| 24 0.219 (0.92%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.42 | 1-year : | 30.52 |
| Resists | First : | 25.19 | Second : | 26.13 |
| Pivot price | 24.33  |
|||
| Supports | First : | 23.67 | Second : | 19.69 |
| MAs | MA(5) : | 23.98 |
MA(20) : | 24.62 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 15.4 |
D(3) : | 18.1 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 26.73 | Low : | 23.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MNTL ] has closed above bottom band by 35.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 24.01 - 24.13 | 24.13 - 24.25 |
| Low: | 23.55 - 23.67 | 23.67 - 23.8 |
| Close: | 23.8 - 24 | 24 - 24.2 |
Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.
Thu, 18 Apr 2024
The Life Sciences Present A Golden Opportunity For Investors. Learn How! - MSN
Mon, 08 Apr 2024
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Yahoo Finance UK
Tue, 19 Mar 2024
Benzinga's 2024 Virtual Healthcare Summit: What's Next In Health? - Elicio Therapeutics (NASDAQ:ELTX) - Benzinga
Tue, 30 Jan 2024
Tema adds neuroscience ETF to thematic offering - ETF Strategy
Fri, 26 Jan 2024
This Week in ETFs: Closures Outnumber New ETFs - ETF Trends
Thu, 25 Jan 2024
US ETF launches from 18th to 25th January, 2024 - ETF Express
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|